Impact of Neoadjuvant Chemotherapy with FOLFOX/FOLFIRI on Disease-Free and Overall Survival of Patients with Colorectal Metastases

Study Aims To determine if neoadjuvant FOLFOX/FOLFIRI is associated with improved disease-free survival (DFS) or overall survival (OS) in patients with colorectal metastases (CRM) to the liver. Methods Ninety-nine patients (from 457 eligible) with CRM that underwent hepatic resection during 2000 to 2005 were included. Group 1 ( n = 44) patients received neoadjuvant FOLFOX/FOLFIRI, and Group 2 ( n = 55) did not receive neoadjuvant therapy. Results There were 58% men. The median age for Group 1 was 58 and Group 2, 64 ( p = 0.03). OS for Group 1 at 1, 3, and 5 years was 93%, 62%, and 51%, respectively, with a median OS of 5.8 years. In Group 2 survival at 1l, 3, and 5 years was 90%, 63%, and 45%, respectively, with a median OS of 3.7 years (HR 1.06, p = 0.87). The DFS for Group 1 at 1, 3, and 5 years was 51%, 20%, and 20%, with a median DFS of 1.1 years and Group 2 at 1, 3, and 5 years was 58%, 32%, and 32% (median DFS—1.2 years; HR = 1.24, p = 0.45). Conclusions Neoadjuvant FOLFOX/FOLFIRI was employed more frequently in younger patients with CRM; however, neoadjuvant chemotherapy for CRM was not significantly associated with an increase in OS or DFS, despite additional adjuvant therapy.